Viatris Long Term Debt 2010-2024 | VTRS

Viatris long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Viatris long term debt for the quarter ending September 30, 2024 was $16.173B, a 13.63% decline year-over-year.
  • Viatris long term debt for 2023 was $16.188B, a 10.14% decline from 2022.
  • Viatris long term debt for 2022 was $18.015B, a 8.63% decline from 2021.
  • Viatris long term debt for 2021 was $19.717B, a 20.85% decline from 2020.
Viatris Annual Long Term Debt
(Millions of US $)
2023 $16,188
2022 $18,015
2021 $19,717
2020 $24,912
2019 $12,175
2018 $13,161
2017 $14,101
2016 $16,562
2015 $6,296
2014 $7,037
2013 $8,856
2012 $6,108
2011 $5,221
2010 $5,634
2009 $5,471
Viatris Quarterly Long Term Debt
(Millions of US $)
2024-09-30 $16,173
2024-06-30 $16,527
2024-03-31 $17,898
2023-12-31 $17,705
2023-09-30 $18,724
2023-06-30 $18,920
2023-03-31 $19,789
2022-12-31 $18,015
2022-09-30 $20,470
2022-06-30 $21,021
2022-03-31 $20,647
2021-12-31 $19,717
2021-09-30 $21,907
2021-06-30 $23,159
2021-03-31 $24,572
2020-12-31 $24,912
2020-09-30 $10,002
2020-06-30 $9,896
2020-03-31 $12,117
2019-12-31 $12,175
2019-09-30 $13,388
2019-06-30 $13,719
2019-03-31 $14,214
2018-12-31 $13,161
2018-09-30 $14,443
2018-06-30 $14,375
2018-03-31 $13,579
2017-12-31 $14,101
2017-09-30 $13,992
2017-06-30 $15,392
2017-03-31 $16,073
2016-12-31 $16,562
2016-09-30 $12,966
2016-06-30 $12,773
2016-03-31 $7,666
2015-12-31 $6,296
2015-09-30 $7,204
2015-06-30 $7,272
2015-03-31 $7,129
2014-12-31 $7,037
2014-09-30 $6,998
2014-06-30 $9,220
2014-03-31 $9,045
2013-12-31 $8,856
2013-09-30 $6,805
2013-06-30 $6,662
2013-03-31 $6,450
2012-12-31 $6,108
2012-09-30 $5,209
2012-06-30 $5,552
2012-03-31 $5,288
2011-12-31 $5,221
2011-09-30 $4,820
2011-06-30 $5,183
2011-03-31 $5,119
2010-12-31 $5,634
2010-09-30 $5,672
2010-06-30 $5,513
2010-03-31 $5,539
2009-12-31 $5,471
2009-09-30 $5,534
2009-06-30 $5,391
2009-03-31 $5,373
Sector Industry Market Cap Revenue
Medical Medical Services $15.576B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $91.424B 11.34
Cencora (COR) United States $47.484B 17.51
DiDi Global (DIDIY) China $23.330B 0.00
Natera (NTRA) United States $21.401B 0.00
ICON (ICLR) Ireland $16.136B 14.37
Avantor (AVTR) United States $13.422B 20.12
Revvity (RVTY) United States $13.376B 23.24
CochLear (CHEOY) Australia $12.844B 0.00
BioMerieux (BMXMF) France $12.666B 0.00
Solventum (SOLV) United States $11.583B 0.00
Medpace Holdings (MEDP) United States $9.789B 27.58
Doximity (DOCS) United States $9.620B 56.63
Charles River Laboratories (CRL) United States $9.516B 18.39
HealthEquity (HQY) United States $8.966B 48.66
Sonic Healthcare (SKHHY) Australia $8.758B 0.00
Bausch + Lomb (BLCO) Canada $6.885B 32.05
Life Times (LTH) United States $5.085B 33.66
Sotera Health (SHC) United States $3.855B 20.62
Organon (OGN) United States $3.757B 3.79
BrightSpring Health Services (BTSG) United States $3.247B 69.07
Surgery Partners (SGRY) United States $2.892B 32.97
PACS (PACS) United States $2.606B 0.00
Concentras Parent (CON) United States $2.581B 0.00
Ardent Health Partners (ARDT) United States $2.375B 0.00
Premier (PINC) United States $2.143B 11.15
Alignment Healthcare (ALHC) United States $2.126B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GeneDx Holdings (WGS) United States $1.952B 0.00
GoodRx Holdings (GDRX) United States $1.616B 42.40
Teladoc Health (TDOC) United States $1.537B 0.00
Pediatrix Medical (MD) United States $1.255B 12.28
CareDx (CDNA) United States $1.183B 0.00
Progyny (PGNY) United States $1.164B 23.57
Establishment Labs Holdings (ESTA) $1.050B 0.00
AMN Healthcare Services Inc (AMN) United States $0.954B 6.46
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Embecta (EMBC) United States $0.778B 5.18
SBC Medicals (SBC) United States $0.677B 0.00
Agilon Health (AGL) United States $0.655B 0.00
InnovAge Holding (INNV) United States $0.647B 0.00
Auna S.A (AUNA) Luxembourg $0.536B 0.00
Sonida Senior Living (SNDA) United States $0.425B 0.00
DocGo (DCGO) United States $0.410B 15.46
Enhabit (EHAB) United States $0.366B 31.61
COMPASS Pathways (CMPS) United Kingdom $0.326B 0.00
LifeMD (LFMD) United States $0.241B 0.00
ModivCare (MODV) United States $0.223B 12.09
Sera Prognostics (SERA) United States $0.209B 0.00
Beauty Health (SKIN) United States $0.200B 0.00
Biodesix (BDSX) United States $0.180B 0.00
Nutex Health (NUTX) United States $0.156B 0.00
Ascend Wellness Holdings (AAWH) United States $0.100B 0.00
So-Young (SY) China $0.092B 22.25
MultiPlan (MPLN) United States $0.084B 0.00
Singular Genomics Systems (OMIC) United States $0.054B 0.00
OncoCyte (OCX) United States $0.043B 0.00
NeueHealth (NEUE) United States $0.041B 1.08
Co-Diagnostics (CODX) United States $0.034B 0.00
Pheton Holdings (PTHL) China $0.030B 0.00
IceCure Medical (ICCM) Israel $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.020B 0.00
Oncology Institute (TOI) United States $0.014B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00